Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.68 |
| ▸ | RAB9A | P51151 | 6/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | POLB | P06746 | 4/20 | 0.68 |
| ▸ | GFER | P55789 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.64 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.54 |
| ▸ | CASP3 | P42574 | 1/20 | 0.52 |
| ▸ | SMO | Q99835 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1494847 | 0.91 | ALDH1A1 (0.72) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL25312016 | 0.79 | ALDH1A1 (0.81) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL29484580 | 0.79 | ALDH1A1 (0.81) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL1494756 | 0.77 | RAB9A (0.79) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL1494819 | 0.77 | ALDH1A1 (1.00) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL4726858 | 0.77 | SMN1; SMN2 (0.78) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL28933829 | 0.77 | ALDH1A1 (0.78) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL4781504 | 0.77 | KDM4E (0.77) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL1494696 | 0.76 | KDM4E (1.00) | KDM4ESMN1; SMN2RAB9ALMNAPOLB | |
| SCHEMBL14076569 | 0.76 | KDM4E (0.72) | KDM4ESMN1; SMN2RAB9ALMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | claimed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | UESUGI MOTONARI (JP) | 2018-03-15 | — | — | US | disclosed |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-19 | — | — | US | disclosed |
| US-20160128985-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-12 | — | — | US | disclosed |
| US-20160128985-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-05-12 | — | — | US | disclosed |
| US-9233941-B2 | Methods and compositions for the treatment of body weight related disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-01-12 | — | — | US | disclosed |
| US-9233941-B2 | Methods and compositions for the treatment of body weight related disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2016-01-12 | — | — | US | disclosed |
| US-20150307501-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE (US) | 2015-10-29 | — | — | US | disclosed |
| US-20140045854-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-13 | — | — | US | disclosed |
| US-20140045854-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-13 | — | — | US | disclosed |
| US-20140038984-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-06 | — | — | US | disclosed |
| US-20140038984-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | BAYLOR COLLEGE OF MEDICINE | 2014-02-06 | — | — | US | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-8486945-B2 | Heterocyclic inhibitors of an Hh-signal cascade, medicinal compositions based thereon and methods for treating diseases caused by the aberrant activity of an Hh-signal system | Ivachtchenko, Alexandre Vasilievich (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2011-03-03 | — | — | US | disclosed |
| WO-2009077956-A2 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | ALLA CHEM, LLC (US) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071289-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER AND RELATED HYPERPROLIFERATIVE DISORDERS | HCCS, PCNA, MKI67 | KDM4E 2557/4885SMN1; SMN2 2848/4885RAB9A 3982/4885 |
| US-20160128985-A1 | Methods and Compositions for the Treatment of Body Weight Related Disorders | ABAT, CPT1B, LRBA | KDM4E 1519/4885SMN1; SMN2 1571/4885RAB9A 4384/4885 |
| US-20140045854-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | HCCS, PCNA, MKI67 | KDM4E 2557/4885SMN1; SMN2 2848/4885RAB9A 3982/4885 |
| US-20150307501-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | FABP4, LIPC, PC | KDM4E 1844/4885SMN1; SMN2 3806/4885RAB9A 3136/4885 |
| US-20110053915-A1 | HETEROCYCLIC INHIBITORS OF AN Hh-SIGNAL CASCADE, MEDICINAL COMPOSITIONS BASED THEREON AND METHODS FOR TREATING DISEASES CAUSED BY THE ABERRANT ACTIVITY OF AN Hh-SIGNAL SYSTEM | SHH, SMO, GLI1 | KDM4E 2294/4885SMN1; SMN2 4057/4885RAB9A 1191/4885 |
| US-20140038984-A1 | Compositions and Methods for the Treatment of Metabolic and Related Disorders | FABP4, LIPC, PC | KDM4E 1844/4885SMN1; SMN2 3806/4885RAB9A 3136/4885 |
| US-20160136164-A1 | Methods and Compositions for the Treatment of Cancer and Related Hyperproliferative Disorders | HCCS, PCNA, MKI67 | KDM4E 2515/4885SMN1; SMN2 2843/4885RAB9A 3989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.